Olympus Corporation
Stock Price Chart
2026/03/02 UpdatedPrice Trend
2026/03/02 UpdatedPrice & Trading Details
2026/03/02 UpdatedPRICE
TRADING
Analyst Recommendations 14 analysts
Updated 2026/03/01Shareholder Composition
Updated 2026/03/01Top Mutual Funds / ETFs
Updated 2026/03/01Major Holders
Updated 2026/03/01| Fund Name | Ownership | Shares | Change |
|---|---|---|---|
|
MFS Series Trust XVII-MFS International Equity Fund
|
21.5M | +5.31% | |
|
Dodge & Cox Funds-Dodge & Cox International Stock Fund
|
21.4M | 0.00% | |
|
VANGUARD STAR FUNDS-Vanguard Total International Stock Index Fund
|
15.7M | +0.05% | |
|
VANGUARD TAX-MANAGED FUNDS-Vanguard Developed Markets Index Fund
|
10.0M | +2.40% | |
|
iShares Trust-iShares Core MSCI EAFE ETF
|
7.8M | 0.00% | |
|
Bridge Builder Trust-Bridge Builder International Equity Fund
|
7.8M | +0.67% |
| Institution | Ownership | Shares | Change |
|---|---|---|---|
|
Pacer Advisors, Inc.
|
12.9K | +8.78% |
Dividend History 4Years Growth
Updated 2026/03/01| Year | Dividend | Change |
|---|---|---|
| 2025 | ¥20 | +11.1% |
| 2024 | ¥18 | +12.5% |
| 2023 | ¥16 | +14.3% |
| 2022 | ¥14 | +16.7% |
| 2021 | ¥12 | - |
Financial Performance
2026/03/01 UpdatedRevenue & Profit
Margins
Cash Flow
Financial Health
| 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|
| Income Statement | ||||
| Revenue | ¥750,123M | ¥881,923M | ¥925,752M | ¥997,332M |
| Gross Profit | ¥506,700M | ¥596,849M | ¥618,432M | ¥683,697M |
| Operating Income | ¥144,696M | ¥186,118M | ¥51,745M | ¥161,996M |
| Pretax Income | ¥147,539M | ¥190,469M | ¥53,907M | ¥165,911M |
| Net Income | ¥115,742M | ¥143,432M | ¥242,566M | ¥117,855M |
| EPS | ¥90.17 | ¥113.08 | ¥199.44 | ¥102.80 |
| Operating Margin | 19.29% | 21.10% | 5.59% | 16.24% |
| Balance Sheet | ||||
| Total Assets | ¥1,357,999M | ¥1,508,701M | ¥1,534,216M | ¥1,432,826M |
| Total Equity | ¥510,168M | ¥640,085M | ¥757,186M | ¥751,733M |
| Total Liabilities | ¥847,831M | ¥868,616M | ¥777,030M | ¥681,093M |
| Cash | ¥302,572M | ¥169,329M | ¥340,933M | ¥252,532M |
| Interest-bearing Debt | ¥386,127M | ¥340,057M | ¥299,616M | ¥229,102M |
| Equity Ratio | 37.57% | 42.43% | 49.35% | 52.47% |
| D/E Ratio | 0.76 | 0.53 | 0.40 | 0.30 |
| Cash Flow | ||||
| Operating CF | ¥169,729M | ¥98,490M | ¥42,365M | ¥190,463M |
| Investing CF | -¥71,016M | -¥58,414M | ¥359,992M | -¥65,469M |
| Financing CF | -¥40,667M | -¥143,178M | -¥276,010M | -¥211,542M |
| Free CF | ¥107,958M | ¥27,867M | -¥22,259M | ¥125,254M |
| Efficiency | ||||
| ROE | 22.69% | 22.41% | 32.04% | 15.68% |
| ROA | 8.52% | 9.51% | 15.81% | 8.23% |
Latest IR Information
-
Notice Regarding Changes of Executive Officers
Effective April 1, 2026, Simone Berger will be appointed Chief Human Resources Officer and David Shang will be appointed Chief Manufacturing and Supply Officer.
Read more -
Notice Regarding Additional Investment in Corporate Venture Capital "Olympus Innovation Ventures Fund II"
Olympus Corporation has decided to make an additional investment in Olympus Innovation Ventures Fund II to strengthen collaboration with early-stage companies.
Read more
Latest News (5 items)
-
Average Analyst Rating: hold
Average Target Price: ¥1,888
Rating Score: 2.71 (Based on 14 analysts)
※1=Strong Buy, 5=Strong Sell
Company Information
About
Olympus Corporation, together with its subsidiaries, manufactures and sells medical equipment in Japan, America, the Middle East, Asia, and Oceania. It operates through Endoscopic Solutions Business, Therapeutic Solutions Business, and Other segments. The company offers gastrointestinal endoscopy system products comprising video endoscopy and ultrasound systems; GI endotherapy products consisting of CRC devices and HPB devices/hemostasis products; endoscopic solutions ecosystem products, including intelligent ecosystem operating software platforms, and AI insights and computer-aided detection/diagnosis products; reprocessing products, such as endoscope reprocessors, chemicals, accessories, and peripherals; and medical services, which include repair center services. It also provides respiratory products comprising bronchoscopy systems and devices, lung cancer products, and chronic obstructive pulmonary disease products; urology products consisting of visualization, stone management, benign prostatic hyperplasia (BPH), and BPH + bladder cancer products; surgical products, such as surgical endoscopy systems, advanced energy devices, surgical microscope, integrated procedure room solutions, and rhino-laryngoscopy systems, as well as surgical devices for the ears, nose, and throat; and gastroenterology devices and gynecology products. The company was formerly known as Olympus Optical Co., Ltd. and changed its name to Olympus Corporation in October 2003. Olympus Corporation was incorporated in 1919 and is headquartered in Hachioji, Japan.